Item 7.01 Regulation FD Disclosure. Members ofHumana Inc.'s (the "Company") senior management team are scheduled to meet with investors at various times betweenDecember 1, 2021 andDecember 31, 2021 . During the meetings, the Company intends to reaffirm its guidance of approximately$23.67 in diluted earnings per common share ("EPS"), or approximately$20.50 in adjusted earnings per common share ("Adjusted EPS"), in each case for the year endingDecember 31, 2021 ("FY 2021"). This guidance is consistent with the guidance issued in Humana's press release datedNovember 3, 2021 . The date and time of presentations to investors are available via the Investor Relations calendar of events on Humana's website at humana.com. The Company has included Adjusted EPS in this current report, a financial measure that is not in accordance with Generally Accepted Accounting Principles ("GAAP"). Management believes that this measure, when presented in conjunction with the comparable measure of GAAP EPS, is useful to both management and its investors in analyzing the Company's ongoing business and operating performance. Consequently, management uses Adjusted EPS as an indicator of the Company's business performance, as well as for operational planning and decision making purposes. Adjusted EPS should be considered in addition to, but not as a substitute for, or superior to, GAAP EPS. A reconciliation of GAAP EPS to Adjusted EPS follows: Diluted earnings per common share FY 2021 Guidance GAAP~$23.67 Amortization of identifiable intangibles ~0.39 Gain on Kindred at Home equity method investment (8.73)
Put/call valuation adjustments associated with company's non-consolidating
3.38 minority interest investments Transaction and integration costs associated with the Kindred at Home 0.61
acquisition
Change in fair market value of publicly-traded equity securities 1.18 Adjusted (non-GAAP) - FY 2021 projected~$20.50
--------------------------------------------------------------------------------
© Edgar Online, source